# Homology Medicines

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/homology-medicines

- Industry: Biotechnology
- Headquarters: Bedford, US
- Website: www.homologymedicines.com
- Total disclosed funding: $127M
- Latest round: Series B (Jul 28, 2017)
- Investors on record: 13

## About

Founded in 2015 and based in Massachusetts, US, Homology Medicines Inc. is a genetic medicines company that provides gene editing and gene therapy technology for patients with rare diseases.

## Funding rounds

- Series B, Jul 28, 2017, $84M — ARCH Venture Partners, Temasek Holdings, HBM Partners, Alexandria Venture Investments, 5AM Ventures, Vivo Capital, OUP (Osage University Partners), Fidelity Investments, Deerfield Management, Rock Springs Capital, Maverick Ventures Israel, Novartis, Vida Ventures
- Series A, Feb 16, 2017, $21M — ARCH Venture Partners, Temasek Holdings, 5AM Ventures, Deerfield Management
- Series A, Dec 22, 2015, $23M — ARCH Venture Partners, Temasek Holdings, 5AM Ventures, Deerfield Management
- Seed, Dec 1, 2015 — Deerfield Management

## Investors

- Deerfield Management (https://capitalatlas.ai/funds/deerfield-management) — Seed, Series A, Series B
- ARCH Venture Partners (https://capitalatlas.ai/funds/arch-venture-partners) — Series A, Series B
- Temasek Holdings — Series A, Series B
- 5AM Ventures (https://capitalatlas.ai/funds/5am-ventures) — Series A, Series B
- HBM Partners (https://capitalatlas.ai/funds/hbm-partners) — Series B
- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series B
- Vivo Capital (https://capitalatlas.ai/funds/vivo-capital) — Series B
- OUP (Osage University Partners) (https://capitalatlas.ai/funds/oup-osage-university-partners) — Series B
- Fidelity Investments (https://capitalatlas.ai/funds/fidelity-investments) — Series B
- Rock Springs Capital — Series B
- Maverick Ventures Israel (https://capitalatlas.ai/funds/maverick-ventures-israel) — Series B
- Novartis — Series B
- Vida Ventures (https://capitalatlas.ai/funds/vida-ventures) — Series B